Clinical trial · Interventional
Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA)
Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia
NCT05088733CI-TRIAL-00055130unknownEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Clinical research of Yang Yin Fu Zheng Jie Du therapy in HBV related hepatocellular carcinoma induced anemia. The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu Zheng Jie Du therapy for patients belong to HBV-HCC induced anemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Routine medical care | Other | — | UNRESOLVED |
| Yang Yin Fu Zheng Jie Du therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Yang Yin Fu Zheng Jie Du therapy
- interventionNames
- Drug: Yang Yin Fu Zheng Jie Du therapy
- Other: Routine medical care
- type
- PLACEBO_COMPARATOR
- label
- Routine medical care
- interventionNames
- Other: Routine medical care
Primary outcomes (1)
- measure
- Survival rate
- timeFrame
- 1 year
Secondary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Meet the criteria of hepatocellular carcinoma * Patients who tested positive for hepatitis B surface antigen (HBsAg) for \>6 months * Meet the criteria of anemia * Ages Eligible for Study: ≤75 years old; * Informed consent from the patient. Exclusion Criteria: * Patients with upper gastrointestinal bleeding within 3 months before enrollment; * History of blood transfusion within 3 months before enrollment; * Patient with other chronic hepatopathy, such as AIH, NAFLD, ALD; * Serious problem of heart, lung, or kidney with severe dysfunction; * Pregnant or child breast feeding women; * Mental or cognitive disorders; * Participating in other drug trials; * Who are allergic to the study drug.
References
Publications (0)
Data not yet available
No reference posted for this study.